This is unpublished

Mohamed
Sorror
M.D.
M.Sc.

he, him, his
Physician & Research Faculty
Pinned
Academic
Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center
Associate Professor of Medicine, Division of Medical Oncology, University of Washington
Sites of Practice
Seattle Cancer Care Alliance

Photo: SCCA

Education, Training, Board Certifications 

  • M.D., Assiut University, Egypt 
  • M.Sc., Assiut University 
  • Residency, Assiut University 
  • Fellowship in Hematology, Assiut University 
  • Fellowship in Medical Oncology, South Egypt Cancer Institute 
  • Fellowship in Medical Oncology, UW 

Clinical Expertise 

  • Hematopoietic stem cell transplantation 
  • Malignant and non-malignant Hematologic diseases 
  • Outcome research and prognostic studies in older and medically infirm cancer patients 

Affiliations

Publications

Research and/or clinical interests 

Dr. Mohamed Sorror’s research is dedicated to improving the care of older and/or medically infirm patients, who are diagnosed with blood cancers. While most people with blood cancers are seniors, studies of new treatments for these diseases routinely exclude them. To solve this problem, Dr. Sorror is gathering evidence and developing decision-making tools to guide the choice of the best treatment for these patients. He leads a large, multi-center, randomized trial testing novel interventions, such as palliative care and dedicated management of individual comorbidities, for patients receiving stem cell transplants to treat blood cancers. Through both clinical and population-based studies, Dr. Sorror aims to optimize the benefits of health care to patients and to society. For example, he is testing, developing and validating methods and tools to predict patient outcomes on treatment, including survival, toxicity and quality of life. He is learning patients’ experiences, preferences and values for cancer treatment. His trials are generating evidence of which interventions work best for which types of patients and under what circumstances. Notably, he and colleagues developed the first scoring system, now used worldwide, for predicting the risks a blood stem cell transplant poses for a particular patient.

Current projects include: 

  • Impact of comorbidities and age on outcomes of allogeneic transplantation 
  • Assessment of biomarkers for prognostic evaluation of transplant outcomes 
  • Predictors of treatment-related mortality after autologous transplantation 
  • Clinical and biological understanding of the roles of comorbidities in development of post-transplant complications 
  • Tools and information to guide choice of therapies is older and medically infirm patients with AML